NBI-31772 (hydrate)

CAT: 0804-HY-110135A-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-110135A-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
NBI-31772 hydrate is a potent inhibitor of interaction between insulin-like growth factor (IGF) and IGF-binding proteins (IGFBPs) . NBI-31772 hydrate is also a nonpeptide ligand that releases bioactive IGF-I from the IGF-I/IGFBP-3 complex (Kis=1-24 nM for all six human subtypes) . Anxiolytic and antidepressant-like effects[1][2][3].
UNSPSC
12352005
Target
IGF-1R
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/nbi-31772-hydrate.html
Purity
99.42
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(C1=CC(O)=C(O)C=C1)C2=NC(C(O)=O)=CC3=C2C=C(O)C(O)=C3.O
Molecular Formula
C17H11NO7.7/4H2O
Molecular Weight
372.82
References & Citations
[1]Liu XJ, et al. Identification of a nonpeptide ligand that releases bioactive insulin-like growth factor-I from its binding protein complex. J Biol Chem. 2001 Aug 31;276 (35) :32419-22.|[2]De Ceuninck F, et al. Pharmacological disruption of insulin-like growth factor 1 binding to IGF-binding proteins restores anabolic responses in human osteoarthritic chondrocytes. Arthritis Res Ther. 2004;6 (5) :R393-403.|[3]Malberg JE, et al, Rosenzweig-Lipson S. Increasing the levels of insulin-like growth factor-I by an IGF binding protein inhibitor produces anxiolytic and antidepressant-like effects. Neuropsychopharmacology. 2007 Nov;32 (11) :2360-8.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Popular Products